STREPSILS INTENSIVE

This brand name is authorized in Nigeria. It is also authorized in Ecuador, Estonia, Ireland, Lithuania, Poland, Romania, South Africa.

Active ingredients

The drug STREPSILS INTENSIVE contains one active pharmaceutical ingredient (API):

1	Flurbiprofen UNII 5GRO578KLP - FLURBIPROFEN
	Flurbiprofen is a propionic acid derivative NSAID which acts through inhibition of prostaglandin synthesis. In humans flurbiprofen has potent analgesic, antipyretic and anti-inflammatory properties.
	Read more about Flurbiprofen

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-9395	Lozenge	Strepsil Intensive Lozenges LOZENGE 8.75 mg 2 x 8's (in PVC-Alu blisters)	Lozenge Round, intagliated, pale yellow to brown, high boiled lozenge with a characteristic taste of honey and lemon 21 RNW-PP-403110 STREPSIL INTENSIVE LOZENGES FLURBIPROFEN 8.75mg Active Ingredient flurbiprofen 8.75mg Excipients with known effects: Glucose 1.069 g/lozenge. Total maximum daily dose (MDD) is 5.345 g. Sucrose 1.407 g/lozenge. Total MDD is 7.035 g. Invert Sugar (Honey) 50.3 mg/lozenge. Total MDD is 0.2515 g. Sulphites-Sulphur Dioxide (E220) 0.137 A4-9395 Drugs Imported Products 28 Over The Counter (OTC) RECKITT BENCKISER NIGERIA LIMITED, HERITAGE PLACE, 21 LUGARD AVENUE , IKOYI LAGOS LAGOS 8174600370 Uzo.Amatokwu@reckitt.com RECKITT BENCKISER HEALTHCARE INT'L LIMITED. NOTTINHAM SITE, THANE ROAD NOTTINGHAMSHIRE NG90 2DB UK., RECKITT BENCKISER HEALTHCARE INT'L LIMITED. NOTTINHAM SITE, THANE ROAD NOTTINGHAMSHIRE NG90 2DB UK, United Kingdom	30/04/2024

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
STREPSILS INTENSIVE Lozenge	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M01AE09	Flurbiprofen	M Musculo-skeletal system → M01 Antiinflammatory and antirheumatic products → M01A Antiinflammatory and antirheumatic products, non-steroids → M01AE Propionic acid derivatives
Discover more medicines within M01AE09
R02AX01		R Respiratory system → R02 Throat preparations → R02A Throat preparations → R02AX Other throat preparations
Discover more medicines within R02AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	5940-MEE-0221, 6439-MEE-0721
EE	Ravimiamet	1317394, 1317406, 1317417, 1508655, 1508666, 1508677, 1739763, 1777484, 1810505
LT	Valstybinė vaistų kontrolės tarnyba	1027230, 1036286, 1036287, 1089165
NG	Registered Drug Product Database	A4-9395
PL	Rejestru Produktów Leczniczych	100097114, 100330504, 100385681
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66075001, W66075002, W66093001, W66093002, W66093003, W66982001, W67603001, W68530001, W68530002, W68530003, W68530004, W68530005, W68531001, W68531002, W68531003, W68531004, W68531005
ZA	Health Products Regulatory Authority	35/16/0015